Overview
- Upstream Bio outlined a Phase 3 program for verekitug in severe asthma and in chronic rhinosinusitis with nasal polyps, with dosing planned to begin in early 2027.
- The company plans to study a high-dose quarterly regimen of up to 400 mg given as a single injection to reach broad patient groups.
- Phase 2 data in severe asthma showed fewer attacks, including a 56% drop with 100 mg every 12 weeks and a 39% drop with 400 mg every 24 weeks, with improved lung function and good tolerance.
- Phase 2 results in chronic rhinosinusitis with nasal polyps met main goals, cutting polyp size and nasal congestion with a safety profile in line with earlier studies.
- Upstream Bio reported $341.5 million in cash expected to fund operations through 2027 and a wider Q4 2025 net loss tied to higher clinical and manufacturing spend for the program.